Allergen Immunotherapy in Asthma
Allergen immunotherapy (AIT) is a specific treatment involving the administration of relevant allergens to allergic patients, with subtypes including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). In asthma, AIT using the house dust mite (HDM) alleviates clinical symptoms and...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/10/11/1406 |
| _version_ | 1827675724656410624 |
|---|---|
| author | Kazuyuki Nakagome Makoto Nagata |
| author_facet | Kazuyuki Nakagome Makoto Nagata |
| author_sort | Kazuyuki Nakagome |
| collection | DOAJ |
| description | Allergen immunotherapy (AIT) is a specific treatment involving the administration of relevant allergens to allergic patients, with subtypes including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). In asthma, AIT using the house dust mite (HDM) alleviates clinical symptoms and decreases airway hyper responsiveness and medication dose. In addition, AIT can improve the natural course of asthma. For example, the effects of AIT can be preserved for at least a few years, even after ending treatment. AIT may increase the remission rate of asthma in children and suppress sensitization to new allergens. If AIT is introduced in pollinosis, AIT may prevent the development of asthma. Moreover, AIT can control other allergic diseases complicated by asthma, such as allergic rhinitis, which also improves the control of asthma. The indication of HDM-SCIT for asthma is mild-to-moderate HDM-sensitized allergic asthma in a patient with normal respiratory function. To date, HDM-SLIT is applicable in Japan for allergic rhinitis, not for asthma. However, the effect of SLIT on asthma has been confirmed internationally, and SLIT is available for asthma in Japan if allergic rhinitis is present as a complication. |
| first_indexed | 2024-03-10T05:09:55Z |
| format | Article |
| id | doaj.art-5d99a033e29844ca85c182e9c2f67498 |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-10T05:09:55Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-5d99a033e29844ca85c182e9c2f674982023-11-23T00:52:50ZengMDPI AGPathogens2076-08172021-10-011011140610.3390/pathogens10111406Allergen Immunotherapy in AsthmaKazuyuki Nakagome0Makoto Nagata1Department of Respiratory Medicine, Saitama Medical University, Saitama 350-0495, JapanDepartment of Respiratory Medicine, Saitama Medical University, Saitama 350-0495, JapanAllergen immunotherapy (AIT) is a specific treatment involving the administration of relevant allergens to allergic patients, with subtypes including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). In asthma, AIT using the house dust mite (HDM) alleviates clinical symptoms and decreases airway hyper responsiveness and medication dose. In addition, AIT can improve the natural course of asthma. For example, the effects of AIT can be preserved for at least a few years, even after ending treatment. AIT may increase the remission rate of asthma in children and suppress sensitization to new allergens. If AIT is introduced in pollinosis, AIT may prevent the development of asthma. Moreover, AIT can control other allergic diseases complicated by asthma, such as allergic rhinitis, which also improves the control of asthma. The indication of HDM-SCIT for asthma is mild-to-moderate HDM-sensitized allergic asthma in a patient with normal respiratory function. To date, HDM-SLIT is applicable in Japan for allergic rhinitis, not for asthma. However, the effect of SLIT on asthma has been confirmed internationally, and SLIT is available for asthma in Japan if allergic rhinitis is present as a complication.https://www.mdpi.com/2076-0817/10/11/1406allergen immunotherapybronchial asthmasubcutaneous immunotherapysublingual immunotherapy |
| spellingShingle | Kazuyuki Nakagome Makoto Nagata Allergen Immunotherapy in Asthma Pathogens allergen immunotherapy bronchial asthma subcutaneous immunotherapy sublingual immunotherapy |
| title | Allergen Immunotherapy in Asthma |
| title_full | Allergen Immunotherapy in Asthma |
| title_fullStr | Allergen Immunotherapy in Asthma |
| title_full_unstemmed | Allergen Immunotherapy in Asthma |
| title_short | Allergen Immunotherapy in Asthma |
| title_sort | allergen immunotherapy in asthma |
| topic | allergen immunotherapy bronchial asthma subcutaneous immunotherapy sublingual immunotherapy |
| url | https://www.mdpi.com/2076-0817/10/11/1406 |
| work_keys_str_mv | AT kazuyukinakagome allergenimmunotherapyinasthma AT makotonagata allergenimmunotherapyinasthma |